Cytosorbents Corp (CTSO) CEO Phillip P. Chan Sells 5,787 Shares
Cytosorbents Corp (NASDAQ:CTSO) CEO Phillip P. Chan sold 5,787 shares of the stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $14.85, for a total transaction of $85,936.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Phillip P. Chan also recently made the following trade(s):
- On Friday, September 7th, Phillip P. Chan sold 11,418 shares of Cytosorbents stock. The stock was sold at an average price of $14.65, for a total transaction of $167,273.70.
Cytosorbents stock traded down $0.10 during trading hours on Friday, hitting $14.10. 186,290 shares of the stock were exchanged, compared to its average volume of 227,094. The company has a current ratio of 8.82, a quick ratio of 8.60 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $446.72 million, a price-to-earnings ratio of -44.06 and a beta of 0.15. Cytosorbents Corp has a 12 month low of $5.25 and a 12 month high of $14.95.
A number of institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp grew its stake in shares of Cytosorbents by 181.8% during the second quarter. Bank of New York Mellon Corp now owns 83,148 shares of the medical research company’s stock valued at $948,000 after purchasing an additional 53,642 shares during the last quarter. MetLife Investment Advisors LLC bought a new position in Cytosorbents in the second quarter valued at approximately $169,000. Metropolitan Life Insurance Co. NY bought a new position in Cytosorbents in the second quarter valued at approximately $119,000. PEAK6 Investments L.P. bought a new position in Cytosorbents in the second quarter valued at approximately $168,000. Finally, Manatuck Hill Partners LLC boosted its stake in Cytosorbents by 4.9% in the second quarter. Manatuck Hill Partners LLC now owns 258,200 shares of the medical research company’s stock valued at $2,943,000 after acquiring an additional 12,000 shares during the last quarter. 24.91% of the stock is currently owned by hedge funds and other institutional investors.
Several research analysts recently issued reports on CTSO shares. Maxim Group set a $13.00 price target on shares of Cytosorbents and gave the stock a “buy” rating in a research report on Tuesday, May 15th. BidaskClub raised shares of Cytosorbents from a “hold” rating to a “buy” rating in a research report on Thursday, May 17th. ValuEngine raised shares of Cytosorbents from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 12th. Finally, Cowen reaffirmed a “buy” rating and set a $15.00 price objective on shares of Cytosorbents in a research note on Friday, August 3rd. Four analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Cytosorbents has an average rating of “Buy” and an average target price of $14.56.
Cytosorbents Company Profile
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Read More: What is the NASDAQ Stock Market?
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.